Literature DB >> 16713981

Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.

Yukai He1, Jiying Zhang, Cara Donahue, Louis D Falo.   

Abstract

The skin contains readily accessible dendritic cells (DCs) with potent antigen presentation function and functional plasticity enabling the integration of antigen specificity with environmentally responsive immune control. Recent studies challenge the established paradigm of cutaneous immune function by suggesting that lymph node-resident DCs, rather than skin-derived DCs (sDCs), are responsible for eliciting T cell immunity against cutaneous pathogens including viral vectors. We show that cutaneous delivery of lentivirus results in direct transfection of sDCs and potent and prolonged antigen presentation. Further, sDCs are the predominant antigen-presenting cells for the induction of potent and durable CD8(+) T cell immunity. These results support the classical paradigm of cutaneous immune function and suggest that antigen presentation by sDCs contributes to the high potency of lentivector-mediated genetic immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713981      PMCID: PMC3077717          DOI: 10.1016/j.immuni.2006.03.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  64 in total

1.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Authors:  Christoph Esslinger; Laurence Chapatte; Daniela Finke; Isabelle Miconnet; Philippe Guillaume; Frédéric Lévy; H Robson MacDonald
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases.

Authors:  Thorsten R Mempel; Sarah E Henrickson; Ulrich H Von Andrian
Journal:  Nature       Date:  2004-01-08       Impact factor: 49.962

3.  Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.

Authors:  Michael J Palmowski; Luciene Lopes; Yasuhiro Ikeda; Mariolina Salio; Vincenzo Cerundolo; Mary K Collins
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

Review 4.  DC-virus interplay: a double edged sword.

Authors:  Marie Larsson; Anne-Sophie Beignon; Nina Bhardwaj
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

Review 5.  Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.

Authors:  William R Heath; Gabrielle T Belz; Georg M N Behrens; Christopher M Smith; Simon P Forehan; Ian A Parish; Gayle M Davey; Nicholas S Wilson; Francis R Carbone; Jose A Villadangos
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

Review 6.  Cutaneous dendritic cells.

Authors:  Jenny Valladeau; Sem Saeland
Journal:  Semin Immunol       Date:  2005-08       Impact factor: 11.130

7.  Mouse lymphoid tissue contains distinct subsets of langerin/CD207 dendritic cells, only one of which represents epidermal-derived Langerhans cells.

Authors:  Patrice Douillard; Patrizia Stoitzner; Christoph H Tripp; Valérie Clair-Moninot; Smina Aït-Yahia; Alex D McLellan; Andreas Eggert; Nikolaus Romani; Sem Saeland
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

8.  Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells.

Authors:  Lidija Bosnjak; Monica Miranda-Saksena; David M Koelle; Ross A Boadle; Cheryl A Jones; Anthony L Cunningham
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

9.  Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity.

Authors:  Vito Racanelli; Sven Erik Behrens; Julio Aliberti; Barbara Rehermann
Journal:  Immunity       Date:  2004-01       Impact factor: 31.745

10.  Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses.

Authors:  Gabrielle T Belz; Christopher M Smith; Daniel Eichner; Ken Shortman; Guna Karupiah; Francis R Carbone; William R Heath
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

View more
  78 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

Review 3.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Authors:  Yuan Hong; Yibing Peng; Michael Mi; Haiyan Xiao; David H Munn; Gui-Qiang Wang; Yukai He
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 5.  Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector.

Authors:  Yukai He; Louis D Falo
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.

Authors:  Kellsye Paula L Fabian; Nina Chi-Sabins; Jennifer L Taylor; Ronald Fecek; Aliyah Weinstein; Walter J Storkus
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

7.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

8.  Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.

Authors:  Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

9.  Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines.

Authors:  Eynav Klechevsky; Maochang Liu; Rimpei Morita; Romain Banchereau; Luann Thompson-Snipes; A Karolina Palucka; Hideki Ueno; Jacques Banchereau
Journal:  Hum Immunol       Date:  2009-02-21       Impact factor: 2.850

10.  Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.

Authors:  Ying Xu; Enzhuo Yang; Jianguang Wang; Rui Li; Guanghua Li; Guoyuan Liu; Na Song; Qi Huang; Cong Kong; Honghai Wang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.